DUBLIN, May 2, 2022
/PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will
report its first quarter 2022 financial results and provide a
business update after market close on Thursday, May 5, 2022. An accompanying conference
call and simultaneous webcast will be hosted at 5:00 pm ET (2:00 pm
PT/10:00 pm IST) that day.
Conference Call Information
To participate in the live
call by telephone, please dial (800) 225-9448 from the US or (203)
518-9783 for international callers, using the conference code
TBPH0505. Those interested in listening to the conference call live
via the internet may do so by visiting Theravance Biopharma's
website at www.theravance.com, under the Investors section,
Presentations and Events.
A replay of the conference call will be available on Theravance
Biopharma's website for 30 days through June
4, 2022. An audio replay will also be available through
11:59 pm ET on May 12, 2022 by dialing (800) 839-1337 from the
US, or (402) 220-0489 for international callers.
About Theravance Biopharma
Theravance Biopharma, Inc. is a biopharmaceutical company
primarily focused on the discovery, development and
commercialization of respiratory medicines. Its core purpose is to
create medicines that help improve the lives of patients suffering
from respiratory illness.
In pursuit of its purpose, Theravance Biopharma leverages
decades of respiratory expertise to discover and develop
transformational medicines that make a difference. These efforts
have led to the development of FDA-approved
YUPELRI® (revefenacin) inhalation solution
indicated for the maintenance treatment of patients with chronic
obstructive pulmonary disease (COPD). Its respiratory pipeline of
internally discovered programs is targeted to address significant
patient respiratory needs.
Theravance Biopharma has an economic interest in potential
future payments from Glaxo Group Limited or one of its
affiliates (GSK) pursuant to its agreements with Innoviva, Inc.
relating to certain programs, including TRELEGY.
For more information, please visit www.theravance.com.
THERAVANCE BIOPHARMA®, THERAVANCE®, and
the Cross/Star logo are registered trademarks of
the Theravance Biopharma group of companies (in
the US and certain other countries).
YUPELRI® is a registered trademark of Mylan
Specialty L.P., a Viatris Company. Trademarks, trade names or
service marks of other companies appearing on this press release
are the property of their respective owners.
Contact Information:
Contact: Gail B. Cohen
Corporate Communications / 917-214-6603
View original content to download
multimedia:https://www.prnewswire.com/news-releases/theravance-biopharma-to-report-first-quarter-2022-financial-results-on-may-5-2022-301536889.html
SOURCE Theravance Biopharma, Inc.